Literature DB >> 10458618

Immune function and phenotype before and after highly active antiretroviral therapy.

S R Søndergaard1, H Aladdin, H Ullum, J Gerstoft, P Skinhøj, B K Pedersen.   

Abstract

Immune functions represented by equal CD4 counts before and after highly active antiretroviral therapy (i.e., pre- and post-HAART) in the same HIV-infected patients, were examined. Twelve HIV-infected patients were included. Patients had equal CD4 counts pre- and post-HAART and were studied on average 30 months pre-HAART and 17 months post-HAART. Post-HAART, CD8+ T cells expressed greater amounts of CD28 (p < .02), smaller amounts of CD38 (p < .02), and a reduced proportion of CD4+CD28+ T cells expressed CD38+ (p < .01). Proliferation increased (p < 10) in lymphocyte cell cultures stimulated with pokeweed mitogens or Candida, and was correlated to expression of CD28 on T cells (p < .02). The proportion of CD3-CD16-CD56+ natural killer (NK) cells increased (p < .05) and CD3-CD16+CD56- NK cells declined (p < .01). Production of interferon-gamma increased (p < .10). The number of naive and memory T cells, the non-major histocompatibility complex (non-MHC)-restricted and HIV-specific MHC-restricted cytotoxicity and the production of macrophage inflammatory protein-1gamma were unchanged. The finding of increased expression of CD28, correlating to increased proliferation capacity, and diminished expression of CD38 on T cells, indicates that following long-term HAART, repopulation occurs with less activated cells with increased proliferative capacity. This finding may be of clinical importance in considering risk and vulnerability for progression of opportunistic infections post-HAART.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458618

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  15 in total

1.  CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.

Authors:  D Scott-Algara; J P Aboulker; C Durier; E Badell; F Marcellin; M Prud'homme; C Jouanne; V Meiffredy; F Brun-Vezinet; G Pialoux; F Raffi
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy.

Authors:  S Resino; I Galán; A Pérez; J A León; E Seoane; D Gurbindo; M Angeles Muñoz-Fernandez
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

3.  Programmed death 1 receptor changes ex vivo in HIV-infected adults following initiation of highly active antiretroviral therapy.

Authors:  Sergei Spitsin; Nancy B Tustin; Eric Riedel; Richard Tustin; Jennifer B Murray; Lauren M Peck; Mohammad Khan; Joseph Quinn; Steven D Douglas
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

4.  Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.

Authors:  J Mittler; P Essunger; G J Yuen; N Clendeninn; M Markowitz; A S Perelson
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.

Authors:  Ronald D'Amico; Yijun Yang; Donna Mildvan; Scott R Evans; Carol T Schnizlein-Bick; Richard Hafner; Nancy Webb; Michael Basar; Robert Zackin; Mark A Jacobson
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

6.  Immunologic basis for revaccination of HIV-infected children receiving HAART.

Authors:  Kaitlin Rainwater-Lovett; William J Moss
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

7.  Proliferation and telomere length in acutely mobilized blood mononuclear cells in HIV infected patients.

Authors:  S R Søndergaard; M V Essen; P Schjerling; H Ullum; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

8.  Attenuation of immune activation in an open-label clinical trial for HIV-AIDS using a polyherbal formulation.

Authors:  Mangaiarkarasi Asokan; Vijaya Sachidanandam; Kadappa Shivappa Satish; Udaykumar Ranga
Journal:  Virusdisease       Date:  2014-05-21

9.  IL-21 augments natural killer effector functions in chronically HIV-infected individuals.

Authors:  Natasa Strbo; Lesley de Armas; Huanliang Liu; Michael A Kolber; Mathias Lichtenheld; Savita Pahwa
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

10.  Tree-Based Methods for Discovery of Association between Flow Cytometry Data and Clinical Endpoints.

Authors:  M Eliot; L Azzoni; C Firnhaber; W Stevens; D K Glencross; I Sanne; L J Montaner; A S Foulkes
Journal:  Adv Bioinformatics       Date:  2010-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.